View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Apr. 30, 2018	May 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Entity Registrant Name	COOPER COMPANIES INC
Entity Central Index Key	0000711404
Current Fiscal Year End Date	--10-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		49,104,101

Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Income Statement [Abstract]
Net sales	$ 631,300	$ 522,400	$ 1,221,300	$ 1,021,500
Cost of sales	226,800	178,500	445,900	365,300
Gross profit	404,500	343,900	775,400	656,200
Selling, general and administrative expense	247,900	193,300	473,800	381,900
Research and development expense	20,800	16,800	39,700	33,100
Amortization of intangibles	36,700	16,700	72,700	33,400
Impairment of intangibles	24,400	0	24,400	0
Operating income	74,700	117,100	164,800	207,800
Interest expense	18,700	7,700	37,100	15,000
Other expense (income), net	2,000	(100)	(1,100)	3,200
Income before income taxes	54,000	109,500	128,800	189,600
(Benefit) provision for income taxes	(6,900)	4,600	190,400	8,900
Net income (loss) attributable to Cooper stockholders	$ 60,900	$ 104,900	$ (61,600)	$ 180,700
Earnings (loss) per share attributable to Cooper stockholders - basic (in dollars per share)	$ 1.24	$ 2.14	$ (1.26)	$ 3.70
Earnings (loss) per share attributable to Cooper stockholders - diluted (in dollars per share)	$ 1.23	$ 2.12	$ (1.26)	$ 3.65
Number of shares used to compute earnings (loss) per share:
Basic (shares)	49,100	49,000	49,000	48,900
Diluted (shares)	49,600	49,500	49,000	49,500

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ 60.9	$ 104.9	$ (61.6)	$ 180.7
Other comprehensive (loss) income:
Foreign currency translation adjustment	(43.0)	38.3	59.3	66.5
Comprehensive income (loss) attributable to Cooper stockholders	$ 17.9	$ 143.2	$ (2.3)	$ 247.2

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Current assets:
Cash and cash equivalents	$ 164.9	$ 88.8
Trade accounts receivable, net of allowance for doubtful accounts of $15.0 at April 30, 2018 and $10.8 at October 31, 2017	432.6	316.6
Inventories	504.8	454.1
Prepaid expense and other current assets	170.1	93.7
Total current assets	1,272.4	953.2
Property, plant and equipment, at cost	1,887.3	1,757.5
Less: accumulated depreciation and amortization	920.8	847.4
Property, plant and equipment, net	966.5	910.1
Goodwill	2,461.1	2,354.8
Other intangibles, net	1,602.0	504.7
Deferred tax assets	36.7	60.3
Other assets	75.7	75.6
Total assets	6,414.4	4,858.7
Current liabilities:
Short-term debt	41.3	23.4
Accounts payable	153.8	142.1
Employee compensation and benefits	77.6	84.1
Other current liabilities	187.7	146.5
Total current liabilities	460.4	396.1
Long-term debt	2,442.4	1,149.3
Deferred tax liabilities	38.0	38.8
Long-term tax payable	176.4	0.0
Accrued pension liability and other	109.2	98.7
Total liabilities	3,226.4	1,682.9
Commitments and contingencies
Stockholders’ equity:
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding	0.0	0.0
Common stock, 10 cents par value, shares authorized: 120.0; issued 52.7 at April 30, 2018 and 52.4 at October 31, 2017	5.3	5.2
Additional paid-in capital	1,542.5	1,526.7
Accumulated other comprehensive loss	(316.0)	(375.3)
Retained earnings	2,371.2	2,434.2
Treasury stock at cost: 3.6 shares at April 30, 2018 and 3.6 shares at October 31, 2017	(415.1)	(415.1)
Noncontrolling interests	0.1	0.1
Stockholders’ equity	3,188.0	3,175.8
Total liabilities and stockholders' equity	$ 6,414.4	$ 4,858.7

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 15.0	$ 10.8
Preferred stock, par value (in dollars per share)	$ 0.1	$ 0.1
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.1	$ 0.1
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	52,700,000	52,400,000
Treasury stock, shares	3,600,000	3,600,000

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Cash flows from operating activities:
Net (loss) income	$ (61.6)	$ 180.7
Depreciation and amortization	135.6	94.0
Impairment of intangibles	24.4	0.0
Increase in operating capital	(187.6)	(59.5)
Other non-cash items	286.3	24.9
Net cash provided by operating activities	197.1	240.1
Cash flows from investing activities:
Purchases of property, plant and equipment	(97.9)	(57.3)
Acquisitions of assets and businesses, net of cash acquired, and other	(1,320.7)	(173.8)
Net cash used in investing activities	(1,418.6)	(231.1)
Cash flows from financing activities:
Proceeds from long-term debt	1,946.1	619.0
Repayments of long-term debt	(650.1)	(374.0)
Net proceeds (repayments) from short-term debt	16.4	(192.4)
Repurchase of common stock	0.0	(29.5)
Net payments related to share-based compensation awards	(10.5)	(10.0)
Dividends on common stock	1.5	1.5
Debt acquisition costs	(3.9)	0.0
Payment of contingent consideration	(0.2)	(3.7)
Proceeds from construction allowance	0.0	2.1
Net cash provided by financing activities	1,296.3	10.0
Effect of exchange rate changes on cash and cash equivalents	1.3	1.5
Net increase in cash and cash equivalents	76.1	20.5
Cash and cash equivalents - beginning of period	88.8	100.8
Cash and cash equivalents - end of period	$ 164.9	$ 121.3

General	6 Months Ended
General	Apr. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited interim consolidated condensed financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of the Cooper Companies, Inc and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2017. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Readers should not assume that the results reported here either indicate or guarantee future performance. Accounting Pronouncements Issued Not Yet Adopted In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220), which allows a reclassification from accumulated other comprehensive income (loss) to retained earnings (accumulated deficit) for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 and requires certain disclosures regarding stranded tax effects in accumulated other comprehensive income (loss). This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted during interim or annual periods. We are currently evaluating the impact of ASU 2018-02 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is presented in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below income from operations. ASU 2017-07 is effective for the Company in fiscal year and interim periods beginning on November 1, 2019, and is not expected to have a significant impact on the Company's consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 provides guidance on the classification and presentation of changes in restricted cash and cash equivalents in the statement of cash flows. ASU 2016-18 will be effective for the Company in fiscal year and interim periods beginning on November 1, 2019, and is not expected to have a significant impact on the Company's Consolidated Statements of Cash Flows. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which requires entities to recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The ASU changes the timing of the recognition of the income tax consequences of non-inventory transfers which under current guidance defers the income tax consequences until the asset is sold to an outside party or otherwise recognized. The guidance for the amendments of ASU 2016-16 requires companies to apply a modified retrospective approach with a cumulative catch-up adjustment to opening retained earnings in the period of adoption. We are currently evaluating the impact of ASU 2016-16 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2018. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of ASU 2016-02, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the update recognized at the date of the initial application along with additional disclosures. We have been monitoring the activity of the FASB and the Transition Resource Group as it relates to specific industry interpretive guidance and further overall interpretations and clarifications. In fiscal year 2017, we began our plan on adoption of ASU 2014-09. Our plan entails activities such as reviewing significant revenue streams (and related costs) and representative contracts to determine the potential changes to existing accounting policies, completion of an accounting guidance gap analysis, and identifying and addressing the impact that ASU 2014-09 will have on business processes, systems and internal controls to support the recognition and disclosure requirements. We are currently in the process of finalizing our accounting gap analysis and monitoring any changes in contracts that may occur prior to our planned adoption on November 1, 2018. We are currently evaluating the full impact of ASU 2014-09 and related amendments on our consolidated financial statements and related disclosures. Currently, we have not identified any material expected changes due to the adoption of ASU 2014-09 on the Company’s consolidated financial statements. We plan to adopt ASU 2014-09, in our fiscal year and interim periods beginning on November 1, 2018 and we currently expect to apply the modified retrospective transition method. This would result in an adjustment to retained earnings for the cumulative effect, if any, of applying the ASU 2014-09 to contracts in process as of the adoption date. Under this method, the Company would not restate the prior consolidated financial statements presented. However, the Company would include additional disclosures of the amount by which each financial statement line item is affected in the current reporting period during our fiscal year 2019, as compared to the guidance that was in effect before the change, and an explanation of the reasons for significant changes, if any. Accounting Pronouncements Recently Adopted In January 2018, the Company adopted ASU 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, which updates the income tax accounting in U.S. generally accepted accounting principles (GAAP) to reflect the SEC interpretive guidance released on December 22, 2017, when the Tax Cuts and Jobs Act of 2017 was signed into law. Additional information regarding the adoption of this standard is contained in Note 6. Income Taxes. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an approximately normal profit margin (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. The Company adopted this guidance on November 1, 2017, and it did not have a material impact on the Company's reported financial results.

Acquisitions

6 Months Ended

Apr. 30, 2018

Business Combinations [Abstract]

Acquisitions

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2018 and 2017:



(In millions)	April 30, 2018	October 31, 2017
Technology	—	71.7
Customer relationships	23.5	43.1
Trademarks	100.0	7.1
Composite intangible asset	1,061.9	—
Other	4.2	—
Total identifiable intangible assets	1,189.6	121.9
Goodwill	67.8	123.1
Net tangible assets (liabilities)	62.4	(4.8	)
Total purchase price	1,319.8	240.2

All the acquisitions were paid in cash and funded by our debt borrowings.

For assets acquisition, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition. For business acquisition, we recorded the tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition.

We believe these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new or complementary products and services.

Fiscal Year 2018

PARAGARD

On November 1, 2017, CooperSurgical acquired the assets of the PARAGARD Intrauterine Device (IUD) business (PARAGARD) from Teva Pharmaceuticals Industries Limited (Teva) for $1.1 billion.

This asset acquisition broadens and strengthens CooperSurgical's current product portfolio. PARAGARD^® is the only hormone-free, long lasting, reversible contraceptive approved by the United States Food and Drug Administration (FDA) available in the United States.

The Company has accounted for the acquisition of PARAGARD as a purchase of assets in accordance with FASB Accounting Standards Codification (ASC) Topic 805, Business Combinations, and ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, whereby the Company recognized assets acquired based on their estimated fair values on the acquisition date. Due to the required screening test, the acquisition does not meet the definition of a business as substantially all the fair value of the gross assets acquired is concentrated in a single identifiable asset. The Company retained independent appraisers to advise management in the determination of the relative fair value of the various assets acquired and liabilities assumed. The values assigned in these financial statements represent management’s best estimate of relative fair values as of the acquisition date.

The following table summarizes the relative fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model:



(In millions)	Relative Fair Value
Composite intangible asset ⁽¹⁾	1,061.9
Assembled workforce intangible asset⁽²⁾	1.2
Property, plant and equipment	2.0
Inventory ⁽³⁾	47.3
Other assets	9.4
Total assets acquired	1,121.8
Less: liabilities assumed	16.4
Total Purchase Price	1,105.4

The Company proportionally allocated the acquisition costs to the net assets acquired. The acquisition-related costs included advisory, legal, valuation and other professional fees.

⁽¹⁾Composite Intangible asset consists of technology, trade name, New Drug Application (NDA) approval and physician relationships, which have been valued as a single composite intangible asset as they are inextricably linked. The composite asset was identified as the primary asset acquired, was valued using the Multi-Period Excess Earnings Method and will be amortized over 15 years.

⁽²⁾An assembled workforce was recognized as a separate acquired intangible asset, given the purchase of assets and will be amortized over 5 years.

⁽³⁾Inventory relative fair value includes step up of $45.4 million.

As PARAGARD was considered an asset purchase as opposed to a business acquisition in accordance with the guidance under FASB ASC 805, Business Combinations, and ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, the Company has not included proforma financial information which is applicable for a business acquisition.

Other Acquisitions

On April 3, 2018, CooperSurgical completed the acquisition of The LifeGlobal Group (LifeGlobal). LifeGlobal was a privately held company that specializes primarily in IVF media. LifeGlobal’s product categories include media products as well as IVF laboratory air filtration products and dishware. The purchase price allocation is preliminary and we are in the process of finalizing information related to assets, liabilities and the corresponding impact on goodwill.

On December 1, 2017, CooperVision acquired Paragon Vision Sciences, a leading provider of orthokeratology (ortho-k) specialty contact lenses and oxygen permeable rigid contact lens materials. Ortho-k contact lenses are overnight lenses which enable corneal topography correction for myopia (nearsightedness) patients. The purchase price allocation is preliminary and we are in the process of finalizing information related to assets, liabilities and the corresponding impact on goodwill.

On January 4, 2018, CooperVision acquired Blueyes Ltd, a long-standing distribution partner, with a leading position in the distribution of contact lenses to the Optical and Pharmacy sector in Israel. The purchase price allocation is preliminary and we are in the process of finalizing information related to assets, liabilities and the corresponding impact on goodwill.

The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our consolidated results of operations.

Fiscal Year 2017

On August 3, 2017, CooperVision completed the acquisition of Procornea Holding B.V. (Procornea). Procornea is a Netherlands based manufacturer and distributor of specialty contact lenses, mainly orthokeratology (ortho-k) which expands CooperVision's access to myopia (nearsightedness) management markets with new products. We have completed the purchase price allocation for this acquisition.

On June 30, 2017, CooperVision completed the acquisition of Grand Vista LLC, a long-standing distribution partner in Russia. Grand Vista LLC is engaged in contact lens and contact lens solutions and lens care product distribution business in Russia. We have completed the purchase price allocation for this acquisition.

On November 4, 2016, CooperSurgical completed the acquisition of Wallace, the in vitro fertilization (IVF) segment of Smiths Medical International, Ltd., a division of Smiths Group plc. Wallace manufactures a range of IVF and ob/gyn products. We have completed the purchase price allocation for this acquisition.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Inventories

6 Months Ended

Apr. 30, 2018

Inventory Disclosure [Abstract]

Inventories



(In millions)	April 30, 2018		October 31, 2017
Raw materials	$	113.0	$	107.0
Work-in-process	13.8		13.3
Finished goods	378.0		333.8
	$	504.8	$	454.1

Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Intangible Assets

6 Months Ended

Apr. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Goodwill



(In millions)	CooperVision		CooperSurgical		Total
Balance at October 31, 2016	$	1,646.4	$	518.3	$	2,164.7
Net additions during the year ended October 31, 2017	28.6		94.4		123.0
Translation	60.7		6.4		67.1
Balance at October 31, 2017	1,735.7		619.1		2,354.8
Net additions during the six months ended April 30, 2018	36.8		31.6		68.4
Translation	34.1		3.8		37.9
Balance at April 30, 2018	$	1,806.6	$	654.5	$	2,461.1

We performed our annual impairment assessment in our third quarter of fiscal 2017 and 2016, and our analysis indicated that we had no impairment of goodwill. We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards.

Other Intangible Assets



	April 30, 2018				October 31, 2017
(In millions)	Gross Carrying Amount		Accumulated Amortization & Translation		Gross Carrying Amount		Accumulated Amortization & Translation		Weighted Average Amortization Period (In years)

Trademarks	$	140.5	$	11.9	$	44.5	$	10.3	17
Composite intangible asset	1,061.9		35.4		—		—		15
Technology	407.9		186.5		428.8		173.2		11
Customer relationships	359.4		158.5		335.5		145.3		13
License and distribution rights and other	75.3		50.7		69.2		44.5		9
	2,045.0		$	443.0	878.0		$	373.3	14
Less: accumulated amortization and translation	443.0				373.3
Other intangible assets, net	$	1,602.0			$	504.7

The estimation of amortization expenses for fiscal 2018 to 2022 for our existing other intangible assets at April 30, 2018, are as follows:



Fiscal year	(In millions)
2018	$	145.4
2019	$	143.3
2020	$	133.0
2021	$	131.6
2022	$	129.5

In the second quarter of fiscal 2018, CooperSurgical recognized an impairment charge of $24.4 million on the intangible assets acquired from Recombine Inc. as the cash flows expected to be generated by this asset group over its estimated remaining life were not sufficient to recover its carrying value. CooperSurgical acquired Recombine Inc. in fiscal 2016, a clinical genetic testing company specializing in carrier screening. The intangible assets impaired consist of Technology, Trademark and Customer relationships.

Debt

6 Months Ended

Apr. 30, 2018

Debt Disclosure [Abstract]

Debt



(In millions)	April 30, 2018			October 31, 2017
Short-term:
Overdraft and other credit facilities	$	41.3		$	23.4
Long term:
Credit agreement	$	194.0		$	323.0
Term loans	2,255.0			830.0
Other	0.2			0.2
Less: unamortized debt issuance cost	(6.8		)	(3.9		)
	$	2,442.4		$	1,149.3

$1.425 billion Term Loan on November 1, 2017 (2017 Term Loan Agreement)

On November 1, 2017, in connection with the PARAGARD acquisition, we entered into a new five-year, $1.425 billion, senior unsecured term loan agreement by and among the Company, the lenders party thereto and DNB Bank ASA, New York Branch, as administrative agent (2017 Term Loan Agreement) which matures on November 1, 2022. The Company used part of the facility to fund the PARAGARD acquisition and used the remainder of the funds to partially repay outstanding borrowings under our revolving credit agreement.

Amounts outstanding under the 2017 Term Loan Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate (each as defined in the 2017 Term Loan Agreement), plus, in each case, an applicable rate of, between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio as defined in the 2017 Term Loan Agreement.

The 2017 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2017 Term Loan Agreement, consistent with the 2016 Credit Agreement discussed below.

Revolving Credit and Term Loan Agreement on March 1, 2016 (2016 Credit Agreement)

On March 1, 2016, we entered into a Revolving Credit and Term Loan Agreement (2016 Credit Agreement), among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The 2016 Credit Agreement provides for a multicurrency revolving credit facility in an aggregate principal amount of $1.0 billion and a term loan facility in an aggregate principal amount of $830.0 million, each of which, unless terminated earlier, mature on March 1, 2021. In addition, we have the ability from time to time to request an increase to the size of the revolving credit facility or establish one or more new term loans under the term loan facility in an aggregate amount up to $750.0 million, subject to the discretionary participation of the lenders.

Amounts outstanding under the 2016 Credit Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate (each as defined in the 2016 Credit Agreement), plus, in each case, an applicable rate of between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2016 Credit Agreement.

We pay an annual commitment fee that ranges from 0.125% to 0.25% of the unused portion of the revolving credit facility depending on certain financial ratios. In addition to the annual commitment fee described above, we are also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2016 Credit Agreement.

At April 30, 2018, we had $830.0 million outstanding under the Term Loan and $805.7 million available under the 2016 Revolving Credit Agreement.

The 2016 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require us to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2016 Credit Agreement:


•	Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times.


•	Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00.

At April 30, 2018, we were in compliance with the Interest Coverage Ratio at 15.68 to 1.00 and the Total Leverage Ratio at 2.67 to 1.00 for both the 2017 Term Loan Agreement and the 2016 Credit Agreement.

Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2017 for more details.

Income Taxes	6 Months Ended
Income Taxes	Apr. 30, 2018
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income Taxes	Income Taxes Recent Tax Legislation The Tax Cuts and Jobs Act (2017 Act) was enacted into law on December 22, 2017 and significantly changes existing U.S. tax law. The 2017 Act adopts a territorial tax system, imposes a mandatory one-time transition tax on earnings of foreign subsidiaries that were previously tax deferred, and reduces the U.S. federal statutory tax rate from 35% to 21%. The reduction in the U.S. federal statutory tax rate is effective on January 1, 2018 which requires the Company to use a blended tax rate for fiscal 2018. Our blended tax rate is 23.34% for fiscal 2018 and is calculated by applying a pro-rated percentage based on the number of days in our fiscal 2018 before and after the January 1, 2018 effective date. For fiscal 2019 and subsequent years, the Company will utilize the enacted U.S. federal statutory tax rate of 21%. The 2017 Act includes several provisions that are effective for our fiscal 2019: (i) tax on global intangible low-taxed income (GILTI) of foreign subsidiaries, (ii) tax on certain payments between a U.S. Corporation and its foreign subsidiaries referred to as the base erosion and anti-abuse tax (BEAT), (iii) limitation on the tax deduction for interest payments, and (iv) expanded limitation on the tax deduction for compensation paid to certain executives. The 2017 Act is effective in the first quarter of fiscal 2018. As of April 30, 2018, we have not completed our accounting for the tax effects of the enactment of the 2017 Act. Consistent with SEC guidance, we recorded a provisional tax expense in our financial statements for the first quarter ending January 31, 2018, based on reasonable estimates of the tax effects of the 2017 Act. The provisional tax expense is subject to revisions as we gather and prepare additional information to complete our analysis of the 2017 Act, and interpret additional guidance issued by the FASB, Internal Revenue Service and U.S. Treasury Department. The provisional tax expense will be finalized during the measurement period, which should not extend beyond one year from the enactment date, and could be materially different than our provisional tax expense. The provisional tax expense is described in more detail below. During the first quarter, the Company recorded a $177.9 million provisional tax expense for the mandatory deemed repatriation of deferred foreign earnings and plans to pay the applicable amounts over eight years. The 2017 Act requires us to incur a one-time transition tax on deferred foreign income not previously subject to U.S. income tax at a rate of 15.5% for foreign cash and certain other net current assets, and 8% on the remaining deferred foreign income. We have not completed our analysis of the transition tax because we are still gathering information and analyzing the earnings and profits, and foreign tax credits which are critical inputs to the calculation. Estimates have been used for fiscal 2017 and part of fiscal 2018 because tax returns have not been filed for those years. During the first quarter, the Company recorded a provisional tax expense of $13.2 million to record changes to the deferred taxes resulting from the U.S. federal rate decreasing from 35% to 21%. The amount is calculated using the applicable tax rates in the years in which the deferred tax assets and liabilities are expected to reverse. The Company is still analyzing certain aspects of the 2017 Act and refining the calculations, which could affect the measurement of the deferred taxes or give rise to new deferred tax amounts. The re-measurement of deferred taxes included in our financial statements will be subject to further revisions if our current estimates vary from our actual future operating results. Due to the changes in the 2017 Act, we are reviewing our prior assertion that earnings from our foreign subsidiaries are indefinitely reinvested. For purposes of recording the provisional tax expense in fiscal 2018, we are no longer asserting that earnings from our foreign subsidiaries are indefinitely reinvested. Accordingly, in the first quarter we recorded provisional estimates relating to additional state income taxes of $8.1 million and withholding taxes of $2.8 million relating to the unremitted foreign earnings. We have not completed our analysis because we are still gathering additional information to quantify the impact to the individual states and to quantify the withholding taxes that would be owed when future dividends are paid to the U.S. As the Company completes its analysis appropriate changes will be made to the financial statements within the measurement period. The 2017 Act imposes a new tax on foreign earnings and profits in excess of a deemed return on tangible assets of foreign subsidiaries referred to as GILTI. The 2017 Act also imposes a new tax on certain payments between a U.S. Corporation and its foreign subsidiaries referred to as BEAT. These new provisions are effective for fiscal 2019. Due to the complexity of the new GILTI and BEAT tax rules, we are continuing to evaluate these new provisions and the application of GAAP. With respect to GILTI, the Company has not progressed sufficiently in its analysis and has not made an accounting policy election to treat taxes due on the GILTI inclusion as a current period expense or factor such amounts into the measurement of our deferred taxes. The Company will continue its evaluation and make a policy election within the measurement period. The 2017 Act limits the future deductions relating to interest expense and certain executive compensation. These provisions are generally effective for the Company in fiscal 2019. Pursuant to transition rules provided in the 2017 Act relating to the deduction for executive compensation, companies will be allowed tax deductions for performance based plans in existence on or before November 2, 2017 and not materially modified after that date. Based on our current interpretation of the transition rules, we believe the Company will be able to deduct the executive compensation relating to those plans. Therefore, we have not recorded any provisional tax expense this quarter or prior quarters. As additional guidance, to clarify the transition rules, is provided by the tax authorities we will make appropriate changes within the measurement period. Effective Tax Rate The Company's effective tax rates were a benefit of 12.9% and expense of 4.2% for the second quarters of fiscal 2018 and 2017, respectively, and an expense of 147.8% and 4.7% for the first six months of fiscal 2018 and 2017, respectively. The decrease in our effective tax rate for the second quarter of fiscal 2018 compared to the second quarter of fiscal 2017 was due primarily to a reduction in U.S. income related to acquisition and integration activities in CooperSurgical. The increase in our effective tax rate for the first six months of fiscal 2018 compared to the first six months of fiscal 2017 was primarily due to the charge of $202.0 million related to the 2017 Act. Our effective tax rate for the first six months of fiscal 2018 was higher than the U.S. Statutory rate because of the discrete tax expense relating to the 2017 Act, which was partially offset by a favorable mix of income from our foreign jurisdictions with lower tax rates and an excess tax benefit from share-based compensation. Our effective tax rate for the first six months of fiscal 2017 was lower than the U.S. Statutory rate primarily because of a favorable mix of income from our foreign jurisdictions with lower tax rates and an excess tax benefit from share-based compensation. We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. As of April 30, 2018 and October 31, 2017, Cooper had unrecognized tax benefits of $63.6 million and $59.9 million respectively. The increase is primarily related to current period transfer pricing. It is our policy to recognize interest and penalties directly related to income taxes as additional income tax expense. It is reasonably possible that $6.1 million of unrecognized tax benefits could be settled during the next twelve months. The Company is subject to United States Federal income tax examinations for fiscal 2015 through 2017 and the Internal Revenue Service has notified the Company that it will audit our U.S. Consolidated Corporation Income Tax Returns for fiscal 2015 and 2016. Cooper remains subject to income tax examinations in other significant tax jurisdictions including the United Kingdom, Japan, France and Australia for the tax years 2013 through 2017. Diverted Profits Tax (DPT) The United Kingdom tax authorities (U.K. Tax Authorities) enacted a Diverted Profits Tax (DPT) as of April 1, 2015 on profits of multinationals that they deemed artificially diverted from the United Kingdom. The tax rate is 25%. DPT is intended to apply in two situations; (a) where a foreign company has artificially avoided having a taxable presence in the United Kingdom and (b) where a group adopts a structure which lacks economic substance in order to divert profits from the United Kingdom. During fiscal 2017, the U.K. Tax Authorities began an inquiry regarding the application of the DPT in fiscal 2015. We believe that the transactions in question were at arm’s length with no intention to divert profit from the United Kingdom and therefore are outside the intended reach of the DPT. On December 20, 2017, the U.K. Tax Authorities issued a DPT charging notice of approximately GBP 31.0 million with respect to the transfer out of the United Kingdom of certain intellectual property rights in connection with the 2014 acquisition of Sauflon Pharmaceutical Ltd. Although taxes were paid on the transfer, the U.K. Tax Authorities are challenging the value assigned to such property. We intend to contest the charging notice vigorously. The process for resolving such a notice can be lengthy and could involve litigation. The DPT legislation provides a one year review period, however, it requires prepayment of the charging notice to be made within 30 days of its issuance. As required, the payment of GBP 31.0 million was made on January 19, 2018. The company continues to cooperate with the U.K. Tax Authorities to resolve this issue. The outcome of this matter cannot be predicted with certainty and may have an adverse impact on our financial condition and results.

(Loss) Earnings Per Share

6 Months Ended

Apr. 30, 2018

Earnings Per Share [Abstract]

(Loss) Earnings Per Share

Earnings (Loss) Per Share



Periods Ended April 30,	Three Months				Six Months
(In millions, except per share amounts)	2018		2017		2018			2017
Net income (loss) attributable to Cooper stockholders	$	60.9	$	104.9	$	(61.6	)	$	180.7
Basic:
Weighted average common shares	49.1		49.0		49.0			48.9
Basic earnings (loss) per common share attributable to Cooper stockholders	$	1.24	$	2.14	$	(1.26	)	$	3.70
Diluted:
Weighted average common shares	49.1		49.0		49.0			48.9
Effect of potential dilutive common shares	0.5		0.5		—			0.6
Diluted weighted average common shares*	49.6		49.5		49.0			49.5
Diluted earnings (loss) per common share attributable to Cooper stockholders	$	1.23	$	2.12	$	(1.26	)	$	3.65
*The number of diluted weighted average common shares used to calculate fiscal 2018 six months diluted loss per share excludes all potentially dilutive instruments because they would be antidilutive due to the net loss position.

The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings (loss) per share calculation because their effect would have been antidilutive for the periods presented:



Periods Ended April 30,	Three Months				Six Months
(In thousands, except exercise prices)	2018		2017		2018	2017
Number of stock option shares excluded	199		192		1,145	234
Range of exercise prices	$	229.66	$	175.31	$15.83-$229.66	$162.28-$175.31
Numbers of restricted stock units excluded	81		1		575	1

Share-Based Compensation Plans

6 Months Ended

Apr. 30, 2018

Share-based Compensation [Abstract]

Share-Based Compensation Plans

Cooper has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2017. The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2018		2017		2018		2017
Selling, general and administrative expense	$	12.8	$	7.6	$	23.6	$	17.2
Cost of sales	0.3		0.8		1.6		2.0
Research and development expense	0.5		0.3		1.1		0.6
Total share-based compensation expense	$	13.6	$	8.7	$	26.3	$	19.8
Related income tax benefit	$	3.1	$	2.6	$	5.6	$	5.9

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Stockholders' Equity

6 Months Ended

Apr. 30, 2018

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Analysis of Changes in Accumulated Other Comprehensive (Loss) Income:



(In millions)	Foreign Currency Translation Adjustment			Minimum Pension Liability			Total
Balance at October 31, 2016	$	(461.4	)	$	(28.2	)	$	(489.6	)
Gross change in value during the year ended October 31, 2017	107.7			10.8			118.5
Tax effect for the period	—			(4.2		)	(4.2		)
Balance at October 31, 2017	$	(353.7	)	$	(21.6	)	$	(375.3	)
Gross change in value during the six months ended April 30, 2018	59.3			—			59.3
Balance at April 30, 2018	$	(294.4	)	$	(21.6	)	$	(316.0	)

Share Repurchases

In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program. In March 2017, the program was amended and approved by the Company's Board of Directors for an increase of $500.0 million providing authorization for a total of $1.0 billion of the Company’s common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements. We did not repurchase shares in the first half of fiscal 2018. During the fiscal year ended October 31, 2017, we repurchased 258 thousand shares of our common stock for $55.0 million. At April 30, 2018, $563.5 million remains authorized for repurchase under the program.

Dividends

We paid a semiannual dividend of approximately $1.5 million or 3 cents per share on February 9, 2018, to stockholders of record on January 23, 2018.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Apr. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements At April 30, 2018 and October 31, 2017, the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. Assets and liabilities are measured and reported at fair value per related accounting standards that define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. We believe that the balances of our revolving credit agreement and term loans approximated their fair values at April 30, 2018 and October 31, 2017 and are categorized as Level 2 of the fair value hierarchy. The Company did not have any derivative assets or liabilities that may include interest rate swaps, cross currency swaps or foreign currency forward contracts at April 30, 2018 and October 31, 2017. Nonrecurring fair value measurements On a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. In the three months ended April 30, 2018, we recorded $24.4 million of impairment charge related to the intangible assets acquired from Recombine Inc. as the cash flows expected to be generated by this asset group over its estimated remaining life were not sufficient to recover its carrying value. The fair value of these intangible assets determined at April 30, 2018 was $0. Our valuation included unobservable Level 3 inputs and was based on expected sales proceeds and discounted cash flows as of April 30, 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Employee Benefits

6 Months Ended

Apr. 30, 2018

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Employee Benefits

Cooper’s Retirement Income Plan (Plan), a defined benefit plan, covers substantially all full-time United States employees. Our contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.

Our results of operations for the three and six months ended April 30, 2018 and 2017, reflect the following components of net periodic pension costs:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2018			2017			2018			2017
Service cost	$	2.7		$	2.5		$	5.4		$	5.0
Interest cost	1.3			1.1			2.5			2.2
Expected return on plan assets	(2.3		)	(1.8		)	(4.6		)	(3.6		)
Recognized net actuarial loss	0.4			0.7			0.8			1.4
Net periodic pension cost	$	2.1		$	2.5		$	4.1		$	5.0

We contributed $2.5 million to the Plan in the first half of fiscal 2018, and expect to contribute $7.5 million during the remainder of fiscal 2018. We contributed $2.5 million to the Plan in the first half of fiscal 2017. The expected rate of return on plan assets for determining net periodic pension cost is 8%.

Contingencies	6 Months Ended
Contingencies	Apr. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Since March 2015, over 50 putative class action complaints were filed by contact lens consumers alleging that contact lens manufacturers, in conjunction with their respective Unilateral Pricing Policy (UPP), conspired to reach agreements between each other and certain distributors and retailers regarding the prices at which certain contact lenses could be sold to consumers. The plaintiffs are seeking damages against CooperVision, Inc., other contact lens manufacturers, distributors and retailers, in various courts around the United States. In June 2015, all of the class action cases were consolidated and transferred to the United States District Court for the Middle District of Florida. In August 2017, CooperVision entered into a settlement agreement with the plaintiffs, without any admission of liability, to settle all claims against CooperVision. The Company recorded a settlement accrual of $3.0 million in the third quarter fiscal ended July 31, 2017. The settlement remains subject to Court approval, and the Court has set a June 19, 2018 hearing date for plaintiffs’ motion for preliminary approval of the settlement. The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred. Diverted Profits Tax (DPT) As discussed in Note 6. Income Taxes, during fiscal 2017, the U.K. Tax Authorities began an inquiry regarding our application of DPT in fiscal 2015. We believe that the transactions in question were at arm’s length with no intention to divert profit from the United Kingdom and therefore are outside the intended reach of the DPT. On December 20, 2017, the U.K. Tax Authorities issued a DPT charging notice of approximately GBP 31.0 million with respect to the transfer out of the United Kingdom of certain intellectual property rights in connection with the 2014 acquisition of Sauflon Pharmaceutical Ltd. Although taxes were paid on the transfer, the U.K. Tax Authorities are challenging the value assigned to such property. We intend to contest the charging notice vigorously. The process for resolving such a notice can be lengthy and could involve litigation. The DPT legislation provides a one year review period, however, it requires prepayment of the charging notice to be made within 30 days of its issuance. As required, the payment of GBP 31.0 million was made on January 19, 2018. The Company continues to cooperate with the U.K. Tax Authorities to resolve this issue. The outcome of this matter cannot be predicted with certainty and may have an adverse impact on our financial condition and results.

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Business Segment Information

6 Months Ended

Apr. 30, 2018

Segment Reporting [Abstract]

Business Segment Information

Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.

Total assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets.

Segment information:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2018			2017			2018			2017
CooperVision net sales by category:
Toric lens	$	150.8		$	131.8		$	288.6		$	252.5
Multifocal lens	49.1			42.9			96.1			85.3
Single-use sphere lens	124.4			104.1			240.7			203.7
Non single-use sphere and other	143.2			129.7			286.9			256.3
Total CooperVision net sales	467.5			408.5			912.3			797.8
CooperSurgical net sales	163.8			113.9			309.0			223.7
Total net sales	$	631.3		$	522.4		$	1,221.3		$	1,021.5
Operating income (loss):
CooperVision	$	123.5		$	112.1		$	235.8		$	199.4
CooperSurgical	(29.8		)	16.8			(39.2		)	33.3
Corporate	(19.0		)	(11.8		)	(31.8		)	(24.9		)
Total operating income	74.7			117.1			164.8			207.8
Interest expense	18.7			7.7			37.1			15.0
Other expense (income), net	2.0			(0.1		)	(1.1		)	3.2
Income before income taxes	$	54.0		$	109.5		$	128.8		$	189.6



(In millions)	April 30, 2018		October 31, 2017
Total assets:
CooperVision	$	3,812.4	$	3,562.6
CooperSurgical	2,334.6		1,107.5
Corporate	267.4		188.6
Total	$	6,414.4	$	4,858.7

Geographic information:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2018		2017		2018		2017
Net sales to external customers by country of domicile:
United States	$	293.2	$	235.3	$	554.6	$	459.5
Europe	210.4		175.6		413.8		343.9
Rest of world	127.7		111.5		252.9		218.1
Total	$	631.3	$	522.4	$	1,221.3	$	1,021.5



(In millions)	April 30, 2018		October 31, 2017
Net property, plant and equipment by country of domicile:
United States	$	495.8	$	472.8
Europe	363.9		352.3
Rest of world	106.8		85.0
Total	$	966.5	$	910.1

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

General (Policies)	6 Months Ended
General (Policies)	Apr. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Pronouncements Issued Not Yet Adopted and Accounting Pronouncements Recently Adopted	Accounting Pronouncements Recently Adopted In January 2018, the Company adopted ASU 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, which updates the income tax accounting in U.S. generally accepted accounting principles (GAAP) to reflect the SEC interpretive guidance released on December 22, 2017, when the Tax Cuts and Jobs Act of 2017 was signed into law. Additional information regarding the adoption of this standard is contained in Note 6. Income Taxes. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an approximately normal profit margin (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. The Company adopted this guidance on November 1, 2017, and it did not have a material impact on the Company's reported financial results.

Acquisitions Acquisitions (Tables)

6 Months Ended

Apr. 30, 2018

Business Combinations [Abstract]

Schedule of Acquisitions

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2018 and 2017:



(In millions)	April 30, 2018	October 31, 2017
Technology	—	71.7
Customer relationships	23.5	43.1
Trademarks	100.0	7.1
Composite intangible asset	1,061.9	—
Other	4.2	—
Total identifiable intangible assets	1,189.6	121.9
Goodwill	67.8	123.1
Net tangible assets (liabilities)	62.4	(4.8	)
Total purchase price	1,319.8	240.2

The following table summarizes the relative fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model:



(In millions)	Relative Fair Value
Composite intangible asset ⁽¹⁾	1,061.9
Assembled workforce intangible asset⁽²⁾	1.2
Property, plant and equipment	2.0
Inventory ⁽³⁾	47.3
Other assets	9.4
Total assets acquired	1,121.8
Less: liabilities assumed	16.4
Total Purchase Price	1,105.4

Inventories (Tables)

6 Months Ended

Apr. 30, 2018

Inventory Disclosure [Abstract]

Schedule of Inventories



(In millions)	April 30, 2018		October 31, 2017
Raw materials	$	113.0	$	107.0
Work-in-process	13.8		13.3
Finished goods	378.0		333.8
	$	504.8	$	454.1

Intangible Assets (Tables)

6 Months Ended

Apr. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Goodwill



(In millions)	CooperVision		CooperSurgical		Total
Balance at October 31, 2016	$	1,646.4	$	518.3	$	2,164.7
Net additions during the year ended October 31, 2017	28.6		94.4		123.0
Translation	60.7		6.4		67.1
Balance at October 31, 2017	1,735.7		619.1		2,354.8
Net additions during the six months ended April 30, 2018	36.8		31.6		68.4
Translation	34.1		3.8		37.9
Balance at April 30, 2018	$	1,806.6	$	654.5	$	2,461.1

Schedule of Other Intangible Assets

Other Intangible Assets



	April 30, 2018				October 31, 2017
(In millions)	Gross Carrying Amount		Accumulated Amortization & Translation		Gross Carrying Amount		Accumulated Amortization & Translation		Weighted Average Amortization Period (In years)

Trademarks	$	140.5	$	11.9	$	44.5	$	10.3	17
Composite intangible asset	1,061.9		35.4		—		—		15
Technology	407.9		186.5		428.8		173.2		11
Customer relationships	359.4		158.5		335.5		145.3		13
License and distribution rights and other	75.3		50.7		69.2		44.5		9
	2,045.0		$	443.0	878.0		$	373.3	14
Less: accumulated amortization and translation	443.0				373.3
Other intangible assets, net	$	1,602.0			$	504.7

Finite-lived Intangible Assets Amortization Expense

The estimation of amortization expenses for fiscal 2018 to 2022 for our existing other intangible assets at April 30, 2018, are as follows:



Fiscal year	(In millions)
2018	$	145.4
2019	$	143.3
2020	$	133.0
2021	$	131.6
2022	$	129.5

Debt (Tables)

6 Months Ended

Apr. 30, 2018

Debt Disclosure [Abstract]

Schedule of Debt



(In millions)	April 30, 2018			October 31, 2017
Short-term:
Overdraft and other credit facilities	$	41.3		$	23.4
Long term:
Credit agreement	$	194.0		$	323.0
Term loans	2,255.0			830.0
Other	0.2			0.2
Less: unamortized debt issuance cost	(6.8		)	(3.9		)
	$	2,442.4		$	1,149.3

(Loss) Earnings Per Share (Tables)

6 Months Ended

Apr. 30, 2018

Earnings Per Share [Abstract]

Schedule of Earnings Per Share



Periods Ended April 30,	Three Months				Six Months
(In millions, except per share amounts)	2018		2017		2018			2017
Net income (loss) attributable to Cooper stockholders	$	60.9	$	104.9	$	(61.6	)	$	180.7
Basic:
Weighted average common shares	49.1		49.0		49.0			48.9
Basic earnings (loss) per common share attributable to Cooper stockholders	$	1.24	$	2.14	$	(1.26	)	$	3.70
Diluted:
Weighted average common shares	49.1		49.0		49.0			48.9
Effect of potential dilutive common shares	0.5		0.5		—			0.6
Diluted weighted average common shares*	49.6		49.5		49.0			49.5
Diluted earnings (loss) per common share attributable to Cooper stockholders	$	1.23	$	2.12	$	(1.26	)	$	3.65
*The number of diluted weighted average common shares used to calculate fiscal 2018 six months diluted loss per share excludes all potentially dilutive instruments because they would be antidilutive due to the net loss position.

Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation



Periods Ended April 30,	Three Months				Six Months
(In thousands, except exercise prices)	2018		2017		2018	2017
Number of stock option shares excluded	199		192		1,145	234
Range of exercise prices	$	229.66	$	175.31	$15.83-$229.66	$162.28-$175.31
Numbers of restricted stock units excluded	81		1		575	1

Share-Based Compensation Plans (Tables)

6 Months Ended

Apr. 30, 2018

Share-based Compensation [Abstract]

Schedule of Compensation Expense and Related Income Tax Benefit for Share-Based Awards

The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2018		2017		2018		2017
Selling, general and administrative expense	$	12.8	$	7.6	$	23.6	$	17.2
Cost of sales	0.3		0.8		1.6		2.0
Research and development expense	0.5		0.3		1.1		0.6
Total share-based compensation expense	$	13.6	$	8.7	$	26.3	$	19.8
Related income tax benefit	$	3.1	$	2.6	$	5.6	$	5.9

Stockholders' Equity (Tables)

6 Months Ended

Apr. 30, 2018

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Analysis of Changes in Accumulated Other Comprehensive (Loss) Income:



(In millions)	Foreign Currency Translation Adjustment			Minimum Pension Liability			Total
Balance at October 31, 2016	$	(461.4	)	$	(28.2	)	$	(489.6	)
Gross change in value during the year ended October 31, 2017	107.7			10.8			118.5
Tax effect for the period	—			(4.2		)	(4.2		)
Balance at October 31, 2017	$	(353.7	)	$	(21.6	)	$	(375.3	)
Gross change in value during the six months ended April 30, 2018	59.3			—			59.3
Balance at April 30, 2018	$	(294.4	)	$	(21.6	)	$	(316.0	)

Employee Benefits (Tables)

6 Months Ended

Apr. 30, 2018

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Schedule of Components of Net Periodic Pension Costs

Our results of operations for the three and six months ended April 30, 2018 and 2017, reflect the following components of net periodic pension costs:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2018			2017			2018			2017
Service cost	$	2.7		$	2.5		$	5.4		$	5.0
Interest cost	1.3			1.1			2.5			2.2
Expected return on plan assets	(2.3		)	(1.8		)	(4.6		)	(3.6		)
Recognized net actuarial loss	0.4			0.7			0.8			1.4
Net periodic pension cost	$	2.1		$	2.5		$	4.1		$	5.0

Business Segment Information (Tables)

6 Months Ended

Apr. 30, 2018

Segment Reporting [Abstract]

Schedule of Segment Information

Segment information:



Periods Ended April 30,	Three Months						Six Months
(In millions)	2018			2017			2018			2017
CooperVision net sales by category:
Toric lens	$	150.8		$	131.8		$	288.6		$	252.5
Multifocal lens	49.1			42.9			96.1			85.3
Single-use sphere lens	124.4			104.1			240.7			203.7
Non single-use sphere and other	143.2			129.7			286.9			256.3
Total CooperVision net sales	467.5			408.5			912.3			797.8
CooperSurgical net sales	163.8			113.9			309.0			223.7
Total net sales	$	631.3		$	522.4		$	1,221.3		$	1,021.5
Operating income (loss):
CooperVision	$	123.5		$	112.1		$	235.8		$	199.4
CooperSurgical	(29.8		)	16.8			(39.2		)	33.3
Corporate	(19.0		)	(11.8		)	(31.8		)	(24.9		)
Total operating income	74.7			117.1			164.8			207.8
Interest expense	18.7			7.7			37.1			15.0
Other expense (income), net	2.0			(0.1		)	(1.1		)	3.2
Income before income taxes	$	54.0		$	109.5		$	128.8		$	189.6

Schedule of Identifiable Assets by Segment



(In millions)	April 30, 2018		October 31, 2017
Total assets:
CooperVision	$	3,812.4	$	3,562.6
CooperSurgical	2,334.6		1,107.5
Corporate	267.4		188.6
Total	$	6,414.4	$	4,858.7

Schedule of Net Sales to External Customers by Country of Domicile

Geographic information:



Periods Ended April 30,	Three Months				Six Months
(In millions)	2018		2017		2018		2017
Net sales to external customers by country of domicile:
United States	$	293.2	$	235.3	$	554.6	$	459.5
Europe	210.4		175.6		413.8		343.9
Rest of world	127.7		111.5		252.9		218.1
Total	$	631.3	$	522.4	$	1,221.3	$	1,021.5

Schedule of Long-Lived Assets by Country of Domicile



(In millions)	April 30, 2018		October 31, 2017
Net property, plant and equipment by country of domicile:
United States	$	495.8	$	472.8
Europe	363.9		352.3
Rest of world	106.8		85.0
Total	$	966.5	$	910.1

Acquisitions (Details) - USD ($) $ in Millions		6 Months Ended	12 Months Ended
Acquisitions (Details) - USD ($) $ in Millions	Nov. 01, 2017	Apr. 30, 2018	Oct. 31, 2017	Oct. 31, 2016
Business Acquisition [Line Items]
Goodwill		$ 2,461.1	$ 2,354.8	$ 2,164.7
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		1,189.6	121.9
Goodwill		67.8	123.1
Total Purchase Price		62.4	(4.8)
Total purchase consideration		1,319.8	240.2
Paragard
Business Acquisition [Line Items]
Total Purchase Price	$ 1,105.4
Total purchase consideration	1,100.0
Property, plant and equipment	2.0
Inventory	47.3
Other assets	9.4
Total assets acquired	1,121.8
Less: liabilities assumed	16.4
Inventory step up	45.4
Technology \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		0.0	71.7
Customer relationships \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		23.5	43.1
Trademarks \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		100.0	7.1
Composite \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		1,061.9	0.0
Composite \| Paragard
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	$ 1,061.9
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Other Intangible Assets \| Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		$ 4.2	$ 0.0
Assembled Workforce \| Paragard
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	$ 1.2
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	5 years

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 113.0	$ 107.0
Work-in-process	13.8	13.3
Finished goods	378.0	333.8
Inventories, net	$ 504.8	$ 454.1

Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2018	Oct. 31, 2017
Goodwill [Roll Forward]
Balance, beginning	$ 2,354.8	$ 2,164.7
Net additions during the six months ended April 30, 2018	68.4	123.0
Translation	37.9	67.1
Balance, ending	2,461.1	2,354.8
CooperVision
Goodwill [Roll Forward]
Balance, beginning	1,735.7	1,646.4
Net additions during the six months ended April 30, 2018	36.8	28.6
Translation	34.1	60.7
Balance, ending	1,806.6	1,735.7
CooperSurgical
Goodwill [Roll Forward]
Balance, beginning	619.1	518.3
Net additions during the six months ended April 30, 2018	31.6	94.4
Translation	3.8	6.4
Balance, ending	$ 654.5	$ 619.1

Intangible Assets (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2018	Oct. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,045.0	$ 878.0
Accumulated Amortization & Translation	$ 443.0	373.3
Finite-Lived Intangible Asset, Useful Life	14 years
Other intangible assets, net	$ 1,602.0	504.7
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	140.5	44.5
Accumulated Amortization & Translation	$ 11.9	10.3
Finite-Lived Intangible Asset, Useful Life	17 years
Composite
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,061.9	0.0
Accumulated Amortization & Translation	$ 35.4	0.0
Finite-Lived Intangible Asset, Useful Life	15 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 407.9	428.8
Accumulated Amortization & Translation	$ 186.5	173.2
Finite-Lived Intangible Asset, Useful Life	11 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 359.4	335.5
Accumulated Amortization & Translation	$ 158.5	145.3
Finite-Lived Intangible Asset, Useful Life	13 years
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 75.3	69.2
Accumulated Amortization & Translation	$ 50.7	$ 44.5
Finite-Lived Intangible Asset, Useful Life	9 years

Intangible Assets (Narrative) (Details) - USD ($)	3 Months Ended	6 Months Ended
Intangible Assets (Narrative) (Details) - USD ($)	Apr. 30, 2017	Apr. 30, 2018
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2018		$ 145,400,000
2019		143,300,000
2020		133,000,000
2021		131,600,000
2022		129,500,000
Goodwill, Impairment Loss	$ 24,400,000	$ 0

Debt (Schedule of Debt) (Details) - USD ($) $ in Millions	6 Months Ended
Debt (Schedule of Debt) (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017	Mar. 01, 2016
Short-term:
Overdraft and other credit facilities	$ 41.3	$ 23.4
Long term:
Credit agreement	194.0	323.0
Term loans	2,255.0	830.0
Other	0.2	0.2
Less: unamortized debt issuance cost	(6.8)	(3.9)
Long-term debt	2,442.4	$ 1,149.3
Senior Notes [Member] \| Senior Unsecured Term Loan Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Amount Outstanding During Period	830.0
2016 Credit Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 805.7
Long term:
Term loans			$ 830.0

Debt (Narrative) (Details)			6 Months Ended	12 Months Ended
Debt (Narrative) (Details)	Nov. 01, 2017 USD ($)	Mar. 01, 2016 USD ($)	Apr. 30, 2018 USD ($)	Oct. 31, 2017 USD ($)
Line of Credit Facility [Line Items]
Term loans			$ 2,255,000,000	$ 830,000,000
Required minimum Interest coverage ratio			3.00
Required maximum total leverage ratio			3.75
Interest coverage ratio			15.68
Total leverage ratio			2.67
Minimum
Line of Credit Facility [Line Items]
Commitment fee percentage		0.125%
Maximum
Line of Credit Facility [Line Items]
Commitment fee percentage		0.25%
2016 Credit Agreement
Line of Credit Facility [Line Items]
Line of credit facility, potential additional borrowing capacity		$ 750,000,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Aggregate commitment amount of credit facility		$ 1,000,000,000.0
2016 Credit Agreement
Line of Credit Facility [Line Items]
Line of credit facility, initiation date		Mar. 01, 2016
Term loans		$ 830,000,000
Line of credit facility interest rate margin on base rate loans percentage		1.00%
Line of credit facility interest rate margin on foreign currency loans percentage		1.75%
Amount available under the credit agreement			$ 805,700,000
2016 Credit Agreement \| Federal Funds Rate
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		0.00%
2016 Credit Agreement \| Eurodollar
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		0.75%
Line of Credit
Line of Credit Facility [Line Items]
Debt instrument, maturity date		Mar. 01, 2021
Two Thousand Seventeen Term Loan Agreement \| Base Rate \| Minimum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate				0.00%
Two Thousand Seventeen Term Loan Agreement \| Base Rate \| Maximum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate				0.75%
Two Thousand Seventeen Term Loan Agreement \| London Interbank Offered Rate (LIBOR) \| Minimum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate				1.00%
Two Thousand Seventeen Term Loan Agreement \| London Interbank Offered Rate (LIBOR) \| Maximum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate				1.75%
Senior Unsecured Term Loan Agreement \| Senior Notes
Line of Credit Facility [Line Items]
Debt term	5 years
Debt instrument, face amount	$ 1,425,000,000.000
Amount outstanding on credit agreement			$ 830,000,000

Income Taxes (Narrative) (Details) £ in Millions, $ in Millions			3 Months Ended		6 Months Ended			12 Months Ended
	Jan. 19, 2018 GBP (£)	Dec. 20, 2017 GBP (£)	Apr. 30, 2018 USD ($)	Apr. 30, 2017	Apr. 30, 2018 GBP (£)	Apr. 30, 2018 USD ($)	Apr. 30, 2017	Oct. 31, 2018	Oct. 31, 2017 USD ($)
Operating Loss Carryforwards [Line Items]
Repatriation tax						$ 177.9
Provisional tax expense						13.2
Current state and local tax expense (benefit)						8.1
Withholding taxes relating to the unremitted foreign earnings			$ 2.8			$ 2.8
Effective income tax rate			12.90%	4.20%	147.80%	147.80%	4.70%
Effective tax rate increase						$ 202.0
Unrecognized tax benefits			$ 63.6			63.6			$ 59.9
Unrecognized tax benefits that could be settled			$ 6.1			$ 6.1
UNITED KINGDOM
Operating Loss Carryforwards [Line Items]
Diverted profit tax \| £		£ 31.0			£ 31.0
Payment for DPT \| £	£ 31.0
Scenario, Forecast
Operating Loss Carryforwards [Line Items]
Blended tax rate								23.34%

(Loss) Earnings Per Share (Schedule of Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Earnings Per Share [Abstract]
Net income (loss) attributable to Cooper stockholders	$ 60,900	$ 104,900	$ (61,600)	$ 180,700
Basic:
Weighted average common shares	49,100	49,000	49,000	48,900
Basic earnings (loss) per common share attributable to Cooper stockholders	$ 1.24	$ 2.14	$ (1.26)	$ 3.70
Diluted:
Effect of potential dilutive common shares	500	500	0	600
Diluted weighted average common shares	49,600	49,500	49,000	49,500
Diluted earnings (loss) per common share attributable to Cooper stockholders	$ 1.23	$ 2.12	$ (1.26)	$ 3.65

(Loss) Earnings Per Share (Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation) (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	199	192	1,145	234
Range of exercise prices, lower limit	$ 229.66	$ 175.31	$ 15.83	$ 162.28
Range of exercise prices, upper limit	$ 229.66	$ 175.31	$ 229.66	$ 175.31
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	81	1	575	1

Share-Based Compensation Plans (Schedule Of Compensation Expense And Related Income Tax Benefit For Share-Based Awards) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 13.6	$ 8.7	$ 26.3	$ 19.8
Related income tax benefit	3.1	2.6	5.6	5.9
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	12.8	7.6	23.6	17.2
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0.3	0.8	1.6	2.0
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0.5	$ 0.3	$ 1.1	$ 0.6

Stockholders' Equity (Schedule of Changes in Accumulated Other Comprehensive Income (Loss))(Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2018	Oct. 31, 2017
Foreign Currency Translation Adjustment [Roll Forward]
Foreign Currency Translation Adjustment, Beginning Balance	$ (353.7)	$ (461.4)
Foreign Currency Translation Adjustment, Gross change in value for the period	59.3	107.7
Foreign Currency Translation Adjustment, Tax effect for the period		0.0
Foreign Currency Translation Adjustment, Ending Balance	(294.4)	(353.7)
Minimum Pension Liability [Roll Forward]
Minimum Pension Liability, Beginning Balance	(21.6)	(28.2)
Minimum Pension Liability, Gross change in value for the period	0.0	10.8
Minimum Pension Liability, Tax effect for the period		(4.2)
Minimum Pension Liability, Ending Balance	(21.6)	(21.6)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Total, Beginning balance	(375.3)	(489.6)
Gross change in value for the period	59.3	118.5
Tax effect for the period		(4.2)
Total, Ending balance	$ (316.0)	$ (375.3)

Stockholders' Equity (Share Repurchases) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Apr. 30, 2018	Oct. 31, 2017	Mar. 31, 2017
Equity [Abstract]
Share Repurchase Program, increase amount			$ 500,000,000
Share Repurchase Program, maximum amount authorized			$ 1,000,000,000.0
Number of common stock repurchased, shares	0	258,000
Common stock repurchased, value		$ 55,000,000
Share Repurchase Program, remaining authorized amount	$ 563,500,000

Stockholders' Equity (Dividends) (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Feb. 09, 2018	Apr. 30, 2018	Apr. 30, 2017
Equity [Abstract]
Dividends on common stock	$ 1.5	$ 1.5	$ 1.5
Cash dividend, per share	$ 0.03
Dividends payable, date of record		Jan. 23, 2018

Fair Value Measurements Fair Value Measurements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Fair Value Disclosures [Abstract]
Impairment of intangibles	$ 24,400,000	$ 0	$ 24,400,000	$ 0
Fair value of intangible assets	$ 0		$ 0

Employee Benefits (Schedule of Components of Net Periodic Pension Costs) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Service cost	$ 2.7	$ 2.5	$ 5.4	$ 5.0
Interest cost	1.3	1.1	2.5	2.2
Expected return on plan assets	(2.3)	(1.8)	(4.6)	(3.6)
Recognized net actuarial loss	0.4	0.7	0.8	1.4
Net periodic pension cost	$ 2.1	$ 2.5	$ 4.1	$ 5.0

Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Defined benefit plan, contributions by employer	$ 2.5	$ 2.5
Defined benefit plan, estimated future employer contributions in current fiscal year	$ 7.5
Expected rate of return on plan assets for determining net periodic pension cost	8.00%

Contingencies (Details) £ in Millions, $ in Millions			6 Months Ended	26 Months Ended
Contingencies (Details) £ in Millions, $ in Millions	Jan. 19, 2018 GBP (£)	Dec. 20, 2017 GBP (£)	Apr. 30, 2018 GBP (£)	Apr. 30, 2017 action	Jul. 31, 2017 USD ($)
Operating Loss Carryforwards [Line Items]
Number of putative class action complaints filed (over) \| action				50
Litigation Settlement, Amount \| $					$ 3.0
UNITED KINGDOM
Operating Loss Carryforwards [Line Items]
Diverted profit tax		£ 31.0	£ 31.0
Payment for DPT	£ 31.0

Business Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Segment Reporting Information [Line Items]
Net sales	$ 631,300	$ 522,400	$ 1,221,300	$ 1,021,500
Operating income (loss)	74,700	117,100	164,800	207,800
Interest expense	18,700	7,700	37,100	15,000
Other expense (income), net	2,000	(100)	(1,100)	3,200
Income before income taxes	54,000	109,500	128,800	189,600
CooperVision
Segment Reporting Information [Line Items]
Net sales	467,500	408,500	912,300	797,800
Operating income (loss)	123,500	112,100	235,800	199,400
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	163,800	113,900	309,000	223,700
Operating income (loss)	(29,800)	16,800	(39,200)	33,300
Corporate
Segment Reporting Information [Line Items]
Operating income (loss)	(19,000)	(11,800)	(31,800)	(24,900)
Toric lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	150,800	131,800	288,600	252,500
Multifocal lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	49,100	42,900	96,100	85,300
Single-use sphere lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	124,400	104,100	240,700	203,700
Non single-use sphere and other \| CooperVision
Segment Reporting Information [Line Items]
Net sales	$ 143,200	$ 129,700	$ 286,900	$ 256,300

Business Segment Information (Schedule of Identifiable Assets By Segment Information) (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 6,414.4	$ 4,858.7
CooperVision
Segment Reporting Information [Line Items]
Total Identifiable assets	3,812.4	3,562.6
CooperSurgical
Segment Reporting Information [Line Items]
Total Identifiable assets	2,334.6	1,107.5
Corporate
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 267.4	$ 188.6

Business Segment Information (Schedule of Net Sales To External Customers By Country Of Domicile) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 631,300	$ 522,400	$ 1,221,300	$ 1,021,500
United States
Segment Reporting Information [Line Items]
Total net sales to external customers	293,200	235,300	554,600	459,500
Europe
Segment Reporting Information [Line Items]
Total net sales to external customers	210,400	175,600	413,800	343,900
Rest of world
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 127,700	$ 111,500	$ 252,900	$ 218,100

Business Segment Information (Schedule of Long-Lived Assets By Country Of Domicile) (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Segment Reporting Information [Line Items]
Total long-lived assets	$ 966.5	$ 910.1
United States
Segment Reporting Information [Line Items]
Total long-lived assets	495.8	472.8
Europe
Segment Reporting Information [Line Items]
Total long-lived assets	363.9	352.3
Rest of world
Segment Reporting Information [Line Items]
Total long-lived assets	$ 106.8	$ 85.0